Satsuma Pharmaceuticals STSA 深 沪
等待开盘 04-02 09:30:00 美东时间
1.10
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.10
- 总市值 3646.78万
- 52周最高 8.08
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.59
- 委 比 0.00%
- 总股本 3315.25万
- 历史最高 36.105
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.59
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Satsuma and SNBL Report Positive Phase 3 Results for STS101 Migraine Nasal Powder
Shin Nippon Biomedical Laboratories Ltd. and Satsuma Pharmaceuticals have announced the publication of new clinical data evaluating STS101 (Dihydroergotamine Nasal Powder, Atzumi™) for the acute treat...
2025-11-05 21:02
Satsuma Pharmaceuticals Gains FDA Approval for Migraine Treatment
Shin Nippon Biomedical Laboratories, Ltd. ( ($JP:2395) ) has issued an update. ...
2025-05-01 11:22
BRIEF-Shin Nippon Biomedical Laboratories Ltd - Subsidiary Satsuma Pharmaceuticals Received Us FDA Approval For Acute Migraine Treatment Atzumi (Sts101)
May 1 (Reuters) - Shin Nippon Biomedical Laboratories Ltd 2395.T: SHIN NIPPON BIOMEDICAL LABORATORIES LTD: SUBSIDIARY SATSUMA PHARMACEUTICALS RECEIVED US FDA APPROVAL FOR ACUTE MIGRAINE TREATMENT ATZU...
2025-05-01 08:09
Shin Nippon Biomedical Laboratories Ltd. Celebrates FDA Approval of Atzumi™ Nasal Powder for Acute Migraine Treatment
Shin Nippon Biomedical Laboratories Ltd., along with its subsidiary, Satsuma Pharmaceuticals, Inc., has received U.S. FDA approval for a 505(b)(2) New Drug Application for Atzumi™ (dihydroergotamine (...
2025-05-01 08:00
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA
NEW YORK, May 3, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or b...
2023-05-03 23:05
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmac...
2023-04-21 20:02
Satsuma Pharmaceuticals (NASDAQ:STSA) Downgraded by HC Wainwright to "Neutral"
HC Wainwright lowered shares of Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rati...
2023-04-19 15:56
FY2023 Earnings Estimate for Satsuma Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:STSA)
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) – Investment analysts ...
2023-04-03 14:02
HC Wainwright（纳斯达克股票代码：STSA）发布的萨摩制药公司的 FY2023 收益预期
Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) – Investment analysts ...
2023-04-03 14:02
